AnaptysBio

AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

A clinical trial flop doesn't leave the biotech a lot of options.

Here's Why AnaptysBio Is Imploding Today

AnaptysBio Inc (NASDAQ: ANAB) shares were taking a huge hit after the company announced a clinical pipeline update along with its third-quarter report.

AnaptysBio Shares Crater On Failed Eczema Study

AnaptysBio stock crashed Friday after the biotech said its experimental eczema treatment failed to pass muster in a Phase 2 study. Shares fell to their lowest-ever point in high volume.

This Biotech Stock Just Crashed 70% To Its Lowest-Ever Point — Here's Why

AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -2.68% and -100.00%, respectively, for the quarter ended September 2019.

AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Lags Revenue Estimates

SAN DIEGO, Nov.  08, 2019  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced topline data from its ATLAS trial, a Phase 2b randomized, double-blinded, placebo-controlled, multi-dose study in approximately 300 adult patients treated with etokimab in moderate-to-severe atopic dermatitis.  Each of the etokimab dosing arms failed to meet the primary endpoint of the trial, which was demonstration of statistically greater improvement in the Eczema Area and Severity Index (EASI) relative placebo at week 16.  The Company will be receiving additional data and plans to provide a detailed update in the first quarter of 2020.

AnaptysBio Reports Etokimab ATLAS Phase 2b Clinical Trial in Moderate-to-Severe Atopic Dermatitis Fails to Meet Primary Endpoint

AnaptysBio, Inc. (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Earnings Preview: AnaptysBio, Inc. (ANAB) Q3 Earnings Expected to Decline

Customers Bancorp

BRP Inc

Top Ranked Momentum Stocks to Buy for October 31st

Investors have lost faith in the biopharma, which is sitting at its lowest market cap in two years. But Wall Street may be overlooking a significant catalyst from a partnered asset.

Is AnaptysBio a Buy?

AnaptysBio (ANAB) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

AnaptysBio (ANAB) Looks Good: Stock Adds 8.1% in Session

The company released some positive data yesterday...that wasn't positive enough.

Here's Why AnaptysBio Stock Fell on Tuesday

AnaptysBio Inc (NASDAQ: ANAB) released topline results Monday from an interim data analysis from a midstage study of its investigational asset ANAB019, which being evaluated for moderate-to-severe generalized pustular psoriasis.

Wedbush: Investors Largely Underappreciating AnaptysBio

AnaptysBio stock toppled Tuesday after the biotech company's psoriasis treatment failed to enthuse investors. The company tested just two patients vs.

This Biotech Stock Plunged As Test Results Failed To Impress

SAN DIEGO, Sept.  30, 2019  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced positive topline data from an interim analysis of its Phase 2 clinical trial of ANB019 in moderate-to-severe generalized pustular psoriasis (GPP) patients, also known as the GALLOP trial. Enrollment is ongoing and AnaptysBio anticipates additional clinical data and a regulatory strategy update for the development of ANB019 in GPP during 2020. Moderate-to-severe GPP is a chronic, life-threatening, rare inflammatory disease with no approved therapies.

AnaptysBio Reports Positive Topline Data from Interim Analysis of GALLOP Phase 2 Clinical Trial of ANB019 Monotherapy in Moderate-to-Severe Generalized Pustular Psoriasis

SAN DIEGO, Sept.  27, 2019  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present at the Cantor Fitzgerald Global 2019 Healthcare Conference on Wednesday, Oct. 2, 2019 at 5:20 p.m. ET in New York City.

AnaptysBio to Present at the Cantor Fitzgerald Global Healthcare Conference

An executive's departure at a sensitive time has investors nervous.

Here's Why AnaptysBio Shares Are Slipping Today

During the second quarter, the company upgraded the safety net under its lead candidate.

AnaptysBio Prepares for a Potential Gear Shift

AnaptysBio stock suffers last week after a rival drug from Regeneron and partner Sanofi fails to beat out Dupixent in an asthma study.

AnaptysBio Tumbles On Rival's Drug Failure; Becomes A Strong Buy On Expanded Pipeline

Regeneron Pharmaceuticals

A potential competitor stumbled in a midstage asthma trial.

Here's Why AnaptysBio Shares Are Sliding Today

Investors love when they find stocks that have the potential to rise 50% to 100% in a fairly short period of time.

Why Credit Suisse Sees AnaptysBio Having 80% to 200% Upside

The clinical-stage biotech hardly made a sound during the first three months of the year

AnaptysBio Started 2019 Quiet as a Ninja

AnaptysBio, Inc. (ANAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

News for AnaptysBio Stock (ANAB)